Medicamen Biotech Receives EU Approval for Paracetamol Registration from Denmark with XGX Pharma

Medicamen Biotech has announced that it has received European Union approval for the registration of paracetamol from Denmark in collaboration with XGX Pharma. This regulatory milestone marks an important development for the pharmaceutical company's international expansion strategy.

Regulatory Approval Details

The EU approval enables the company to market and distribute paracetamol products across European Union member states. The registration was obtained from Denmark, which serves as the reference member state for this particular pharmaceutical product.

Parameter:	Details
Product:	Paracetamol
Approval Authority:	European Union
Reference Country:	Denmark
Partner:	XGX Pharma

Strategic Partnership

The collaboration with XGX Pharma demonstrates Medicamen Biotech's approach to leveraging strategic partnerships for regulatory approvals and market access. This partnership facilitates the company's entry into the European pharmaceutical market with its paracetamol formulation.

Market Implications

The EU approval provides Medicamen Biotech with access to one of the world's largest pharmaceutical markets. Paracetamol, being a widely used analgesic and antipyretic medication, represents a significant market opportunity across European territories. This regulatory success strengthens the company's pharmaceutical portfolio and enhances its competitive position in the international market.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+0.88%	+4.89%	+9.85%	+0.74%	-21.00%	-27.50%

Medicamen Biotech Limited, a prominent player in the biotech sector, has announced its financial results for the second quarter and half-year ended September 30, 2025, showcasing robust performance and improved liquidity position.

Financial Highlights

The company's Board of Directors approved the unaudited standalone and consolidated financial results, revealing noteworthy figures:

Metric	Amount (in Rs.)
Net Profit After Tax (Standalone)	304.22 lakhs
Cash and Bank Balances	4,351.23 lakhs
Previous Year Cash and Bank Balances	358.03 lakhs
Increase in Cash and Bank Balances	3,993.20 lakhs

Significant Cash Position Improvement

One of the most striking aspects of Medicamen Biotech's financial report is the substantial increase in its cash and bank balances. The company's liquid assets grew from Rs. 358.03 lakhs in the previous year to Rs. 4,351.23 lakhs, marking a remarkable growth of approximately 1,115%.

Capital Raising Success

The dramatic improvement in Medicamen Biotech's cash position can be attributed to successful capital raising activities. The company reported:

Capital Raising Activity	Amount (in Rs.)
Proceeds from Share Capital Issuance	84.82 lakhs
Securities Premium	4,410.72 lakhs
Total Capital Raised	4,495.54 lakhs

This capital infusion has significantly bolstered the company's financial standing, providing a strong foundation for future growth and operational expansion.

Regulatory Compliance

In compliance with the Securities and Exchange Board of India (SEBI) Listing Obligations and Disclosure Requirements Regulations, 2015, Medicamen Biotech's Board of Directors convened on November 14, 2025, to approve these financial results. The meeting began at 2:30 PM and concluded at 3:45 PM.

The company has also submitted Limited Review Reports from Rai Qimat & Associates, Chartered Accountants, for both standalone and consolidated financial results, ensuring transparency and adherence to regulatory standards.

Investors and stakeholders can access the detailed unaudited financial results for the quarter and half-year ended September 30, 2025, on the company's official website at www.medicamen.com .

This strong financial performance, particularly the enhanced cash position, positions Medicamen Biotech favorably for potential future initiatives in the dynamic biotech sector.